Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Medjet

This article was originally published in The Gray Sheet

Executive Summary

Medjet: Expecting net proceeds of $4.9 mil. from an initial public offering of 1.2 mil. to 1.6 mil. units at a projected price of $5 per unit. The Edison, New Jersey-based company filed a registration statement with SEC for the offering April 3. Each unit consists of one share of common stock and one warrant exercisable at $10 per share. The offering is being underwritten on a "best efforts" basis by Patterson Travis. Prior to completion of the offering, Medjet will effect a stock split, the ratio of which will be determined "based upon the number of units anticipated by the company and the underwriter to be sold in the offering," the SEC filing states.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel